Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T13:35:42.546Z.
Calculation as of: 2026-10-06T13:35:42.546Z.
Quote observation: 2026-10-06T13:34:47.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2e8745362276acfcd64f5b9abcba69827836693d7b304a16c872192b0535814a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Bicara Therapeutics Inc. Common Stock
Market Cap
$1.15B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.15B
Price/OCF Ratio
183.99
TTM Avg
131.82
3Y Avg
1823.85
5Y Avg
1138.24
Market Cap
$1.12B
Price/OCF Ratio
6.04
TTM Avg
6.67
3Y Avg
9.62
5Y Avg
13.32
Market Cap
$1.17B
Price/OCF Ratio
5.79
TTM Avg
5.50
3Y Avg
12.06
5Y Avg
21.65
Market Cap
$1.15B
Price/OCF Ratio
27.09
TTM Avg
16.06
3Y Avg
17.84
5Y Avg
17.84
Market Cap
$1.12B
Price/OCF Ratio
41.10
TTM Avg
44.73
3Y Avg
38.92
5Y Avg
41.24
Market Cap
$1.20B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.22B
Price/OCF Ratio
18.88
TTM Avg
22.01
3Y Avg
32.46
5Y Avg
37.26
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bicara Therapeutics Inc. Common Stock (BCAX) | $1.15B | N/A | N/A | N/A | N/A |
| Harrow Health, Inc. (HROW)vs › | $1.15B | 183.99 | 131.82 | 1823.85 | 1138.24 |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.12B | 6.04 | 6.67 | 9.62 | 13.32 |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.17B | 5.79 | 5.50 | 12.06 | 21.65 |
| Castle Biosciences, Inc. (CSTL)vs › | $1.15B | 27.09 | 16.06 | 17.84 | 17.84 |
| IRadimed Corporation (IRMD)vs › | $1.12B | 41.10 | 44.73 | 38.92 | 41.24 |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | N/A | N/A | N/A | N/A |
| Cronos Group Inc. (CRON)vs › | $1.22B | 20.33 | 36.33 | 71.26 | 71.26 |
| Innovage Holding Corp. (INNV)vs › | $1.22B | 18.88 | 22.01 | 32.46 | 37.26 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.02B | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
